Shankara Paneesha

Haemato-oncologist @uhbtrust & Honorary Associate Clinical Professor UoB interested in lymphoma, myeloma, CLL & transplantation. Firm believer in patient choice

[Shankara Paneesha @Paneeshas]

Great debate @UKCHART annual Education Day
MRD adapted treatment discontinuation in myeloma
@profBigG @profghjackson

[Shankara Paneesha @Paneeshas]

Great news for our patients

[Toby Eyre @tobyeyre82]

BeOne Medicines’ BEQALZI™ (sonrotoclax) Approved by U.S. FDA as First and Only BCL2 Inhibitor for R/R Mantle Cell Lymphoma - https://t.co/5cjKG42QLq

[Shankara Paneesha @Paneeshas]

Exciting trial!
Wish it was a multi national study
Whether platform trial with pick the winner may be better for RT

[Mazyar Shadman, MD MPH @mshadman]

Excited to kick-off the @SWOG S2504 trial which is the first randomized trial for Richter Transformation (RT) in the US:
Pirtobrutinib with RCHOP vs. RCHOP is TN RT
Asking all #CLL and #lymphoma experts to participate and spread the word.

Special thanks to @DebbieMStephens the study co-chair and @DanilovLab the TM chair. Thanks to @NCIMedia and @EliLillyandCo

@CllSociety @lymphoma @SOU_LnL_Fund
@fredhutch @cityofhope @UNC_Lineberger

[Bread & Butter Haematology @MorphologyAmigo]

Conferences are great for CPD- much of what we hear isn’t immediately usable in our system.

Let experts distil it down😀
👇Join the brilliant @Paneeshas @VidhyaMurthy1 & others
I learnt a lot from both
Maybe they teach you a thing or two :)
#medicine #hematology #medtwitter

[Shankara Paneesha @Paneeshas]

@mshadman looking for your presentation
Maybe the new SOC for fixed duration treatment in CLL

[Mazyar Shadman, MD MPH @mshadman]

CELESTIAL-2 is official. Will present the TIP abstract at #ASCO26

Zanubrutinib plus Sonrotoclax (ZS) vs. Acalabrutinib plus Venetoclax for TN #CLL

What will be the best all oral FD treatment for CLL?

https://t.co/2IXGtqY6MG

@fredhutch

[Shankara Paneesha @Paneeshas]

Excellent opportunity to catch up with the updates from summer congress with national haematology speakers

[Sridhar Chaganti @SridharChaganti]

Join us for the Summer Congress Insights meeting in Birmingham on Friday 26th June. Updates from ASCO and EHA by leading clinicians in the field. A fantastic opportunity for networking too. For more details: https://t.co/ImgmE1UCRI
To register: https://t.co/velnBjLa13

[Shankara Paneesha @Paneeshas]

Great news for our patients

[Graham Collins @graham74GC]

Finally! A NICE approved bispecific in released / refractory follicular lymphoma. Great news. #lymsm

[Shankara Paneesha @Paneeshas]

@ShashiTharoor @SalimShafeek5 @ShashiTharoor My heartfelt condolences to Shabnum and family

[Shankara Paneesha @Paneeshas]

@graham74GC wonderful data
Good to understand biological rational other than circadian rhythm
Not sure whether we have any cytokines data

[Graham Collins @graham74GC]

Intriguing data from Luan et al. Time of CAR-T infusion may influence outcome.
• multicentre retrospect, 1052 pts
• rel / ref DLBCL
• med infn time 11.48am
• every hr later assoc with worse outcome
• 1y PFS 51% < 12pm, 35% > 12pm
#lymsm

https://t.co/D6j718GRqB

[Shankara Paneesha @Paneeshas]

@tonyiommi Happy new year

[Shankara Paneesha @Paneeshas]

@tonyiommi Merry Christmas and happy new year
Grateful for everything you do

[Shankara Paneesha @Paneeshas]

@DaniilMedwed Where are you in India

[Shankara Paneesha @Paneeshas]

@tonyiommi Thanks for all your support to @UHBCharity and our patients

[Tony Iommi @tonyiommi]

A massive thank you to everyone who bought tickets to my guitar raffle these past few weeks. Together you've raised over £50,000 for the Heartlands Hospital Charity appeal. What an incredible achievement and only possible thanks to all of you 🖤 - Tony

Keep an eye on your inbox for an email to the winner.

[Shankara Paneesha @Paneeshas]

Great work from Bham team
Vaishali and Sridhar great leadership and performance

[Sridhar Chaganti @SridharChaganti]

Fantastic talk today by Vaishali Dulobdas at #ASH2025 on effect of immune parameters and IgRT on post CD19 CAR T outcomes. #lymsm #uhbtrust #nickduncan31 @Capt__Kirkwood @immunologydoc @lymphomule @CCHBham @Paneeshas @lymphomahub @DrLindsayG

[Shankara Paneesha @Paneeshas]

Important data so now we can make individual treatment decisions based on patient choice and other considerations

[Toby Eyre @tobyeyre82]

Fixed-Duration versus Continuous Treatment for Chronic Lymphocytic Leukemia | New England Journal of Medicine https://t.co/qVBBy7u780

[Shankara Paneesha @Paneeshas]

Another great choice for our patients

[Mazyar Shadman, MD MPH @mshadman]

Pirtobrutinib is now approved for pts with #CLL after cBTKi.

Pirtobrutinib can now be used in second line, potentially.

Big #ASH25 for pirtobrutinib!

https://t.co/IBjAEJaQNV

[Shankara Paneesha @Paneeshas]

@mshadman
Great talk and very informative discussions

[Mazyar Shadman, MD MPH @mshadman]

@FWANDROO @Paneeshas @paulmos63832199 @BritSocHaem @SWBHnhs @MidlandMetUH @SalimShafeek5 @MorphologyAmigo It was nice to meet you all and thanks for the great discussion!

[Shankara Paneesha @Paneeshas]

Another great choice for our patients

[Toby Eyre @tobyeyre82]

Zanubrutinib approved for relapsed #MCL by @NICEComms #lymsm
Final draft guidance avaliable
https://t.co/3f3VJHbTbA

[Shankara Paneesha @Paneeshas]

Measurable Residual Disease–Guided Therapy for Chronic Lymphocytic Leukemia | NEJM https://t.co/bJu6QFik18
Great work from UK Team! Undetectable MRD and extended progression-free survival were more common with ibrutinib–venetoclax than with ibrutinib alone

[Toby Eyre @tobyeyre82]

➡️➡️Big CLL news!
Munir et al
OS and PFS adv for MRD driven I&V over ibrutinib in 1L #CLL #EHA2025
Congrats to all FLAIR trial 🇬🇧group
Measurable Residual Disease–Guided Therapy for Chronic Lymphocytic Leukemia | New England Journal of Medicine https://t.co/7Odds8kWZK